Title of article :
Effects of FK317, a novel anti-cancer agent, on survival of mice bearing B16BL6 melanoma and Lewis lung carcinoma
Author/Authors :
Inami، نويسنده , , Masamichi and Kawamura، نويسنده , , Ikuo and Tsujimoto، نويسنده , , Susumu and Nishigaki، نويسنده , , Fusako and Matsumoto، نويسنده , , Sanae and Naoe، نويسنده , , Yoshinori and Sasakawa، نويسنده , , Yuka and Matsuo، نويسنده , , Masahiko and Manda، نويسنده , , Toshitaka and Goto، نويسنده , , Toshio، نويسنده ,
Issue Information :
روزنامه با شماره پیاپی سال 2002
Abstract :
The effects of FK317 (11-acetyl-8-carbamoyloxymethyl-4-formyl-6-methoxy-14-oxa-1,11-diazatetraacylo[7.4.1.02,7.010,2]tetradeca-2,4,6-trien-9-yl acetate), a novel anti-cancer agent, and mitomycin C (MMC) on survival time of mice bearing B16BL6 melanoma and Lewis lung carcinoma (LLC), induced by intravenous inoculation of the tumor, were investigated. Treatment with FK317 resulted in a significant prolongation of survival time in both tumor models. Four of ten mice bearing B16BL6 were disease-free following FK317 treatment. In contrast, MMC was not effective in prolonging survival time. Overall, this study demonstrated that FK317 shows more potent survival extension in mice bearing B16BL6 and LLC than MMC, suggesting that FK317 may have therapeutic utility for cancer chemotherapy.
Keywords :
Survival extension , B16BL6 melanoma , Lewis lung carcinoma , FK317 , Mitomycin C
Journal title :
Cancer Letters
Journal title :
Cancer Letters
